These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 27609859)
1. Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study. Mackenzie IS; Ford I; Walker A; Hawkey C; Begg A; Avery A; Taggar J; Wei L; Struthers AD; MacDonald TM; BMJ Open; 2016 Sep; 6(9):e013774. PubMed ID: 27609859 [TBL] [Abstract][Full Text] [Related]
2. Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation. Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM; Health Technol Assess; 2024 Mar; 28(18):1-55. PubMed ID: 38551218 [TBL] [Abstract][Full Text] [Related]
3. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Mackenzie IS; Hawkey CJ; Ford I; Greenlaw N; Pigazzani F; Rogers A; Struthers AD; Begg AG; Wei L; Avery AJ; Taggar JS; Walker A; Duce SL; Barr RJ; Dumbleton JS; Rooke ED; Townend JN; Ritchie LD; MacDonald TM; Lancet; 2022 Oct; 400(10359):1195-1205. PubMed ID: 36216006 [TBL] [Abstract][Full Text] [Related]
4. Randomised, double-blind, placebo-controlled study evaluating the effect of allopurinol on the risk of cardiovascular events in patients with high and very high cardiovascular risk, including the presence of long-COVID-19 syndrome: the ALL-VASCOR study protocol. Lewandowska K; Lipski D; Uruski P; Narkiewicz K; Januszewicz A; Wolf J; Prejbisz A; Rajzer M; Więcek A; Tykarski A BMJ Open; 2024 Jul; 14(7):e075741. PubMed ID: 39053954 [TBL] [Abstract][Full Text] [Related]
5. Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. Rorie DA; Rogers A; Mackenzie IS; Ford I; Webb DJ; Willams B; Brown M; Poulter N; Findlay E; Saywood W; MacDonald TM BMJ Open; 2016 Feb; 6(2):e010313. PubMed ID: 26861939 [TBL] [Abstract][Full Text] [Related]
6. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study. Zhang M; Solomon DH; Desai RJ; Kang EH; Liu J; Neogi T; Kim SC Circulation; 2018 Sep; 138(11):1116-1126. PubMed ID: 29899013 [TBL] [Abstract][Full Text] [Related]
8. A multicentre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and health-care resource use following cardiac surgery (TITRe2). Reeves BC; Pike K; Rogers CA; Brierley RC; Stokes EA; Wordsworth S; Nash RL; Miles A; Mumford AD; Cohen A; Angelini GD; Murphy GJ Health Technol Assess; 2016 Aug; 20(60):1-260. PubMed ID: 27527344 [TBL] [Abstract][Full Text] [Related]
9. Patient-reported gout attack frequency and allopurinol use in general practice in the Netherlands: a prospective observational cohort study protocol. van Leeuwen KDB; Bohnen AM; Jacobs ML; van Der Lei J; Janssens HJEM; Koffeman AR; Bindels PJE; Bierma-Zeinstra SMA BMJ Open; 2018 Nov; 8(11):e024335. PubMed ID: 30478125 [TBL] [Abstract][Full Text] [Related]
10. Evaluating Diuretics in Normal Care (EVIDENCE): protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertension. Rogers A; Flynn A; Mackenzie IS; McConnachie L; Barr R; Flynn RWV; Morant S; MacDonald TM; Doney A Trials; 2021 Nov; 22(1):814. PubMed ID: 34789314 [TBL] [Abstract][Full Text] [Related]
11. Allopurinol as a cardiovascular drug. Kelkar A; Kuo A; Frishman WH Cardiol Rev; 2011; 19(6):265-71. PubMed ID: 21983313 [TBL] [Abstract][Full Text] [Related]
12. The effects of xanthine oxidase inhibitor in patients with chronic heart failure complicated with hyperuricemia: a prospective randomized controlled clinical trial of topiroxostat vs allopurinol-study protocol. Sakuma M; Toyoda S; Arikawa T; Koyabu Y; Kato T; Adachi T; Suwa H; Narita JI; Anraku K; Ishimura K; Yamauchi F; Sato Y; Inoue T; Clin Exp Nephrol; 2018 Dec; 22(6):1379-1386. PubMed ID: 29916098 [TBL] [Abstract][Full Text] [Related]
14. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study. Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635 [TBL] [Abstract][Full Text] [Related]
15. Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study. Weisman A; Tomlinson GA; Lipscombe LL; Perkins BA; Hawker GA Diabetes Obes Metab; 2019 Jun; 21(6):1322-1329. PubMed ID: 30734980 [TBL] [Abstract][Full Text] [Related]
16. Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial. Dawson J; Robertson M; Dickie DA; Bath P; Forbes K; Quinn T; Broomfield NM; Dani K; Doney A; Houston G; Lees KR; Muir KW; Struthers A; Walters M; Barber M; Bhalla A; Cameron A; Dyker A; Guyler P; Hassan A; Kearney MT; Keegan B; Lakshmanan S; Macleod MJ; Randall M; Shaw L; Subramanian G; Werring D; McConnachie A EClinicalMedicine; 2023 Mar; 57():101863. PubMed ID: 36864979 [TBL] [Abstract][Full Text] [Related]
17. Assessment of dialysis initiation by a fuzzy mathematics equation (ADIFE): a study protocol for a randomised controlled trial. Chen J; Liu Y; Chen X; Sun X; Li W; Yang W; Li P; Sun X; Wang D; Jiang H; Shi W; Liu W; Fu P; Ding X; Chang M; Liu S; Yang X; Cao N; Chen M; Ni Z; Chen J; Sun S; Liang X; Wang H; He Y; Gao B; Wang J; Hao L; Liu J; Li S; He Q; Liu H; Yi N; Shao F; Jiao J; Ma Y; Yao L; Sun Y; Li D; Szczech L; Fang M; Odeh Z; Lin H BMJ Open; 2019 Sep; 9(9):e023162. PubMed ID: 31501092 [TBL] [Abstract][Full Text] [Related]
18. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644 [TBL] [Abstract][Full Text] [Related]
19. Allopurinol as a therapeutic option in cardiovascular disease. Okafor ON; Farrington K; Gorog DA Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655 [TBL] [Abstract][Full Text] [Related]
20. Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD/HP vs HD): study protocol. Lu W; Jiang GR; BMJ Open; 2018 Jul; 8(7):e022169. PubMed ID: 30056391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]